2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
65
Neoplasm Metastasis
6
Prostatic Neoplasms, Castration-Resistant
5
Non-metastatic Castration-resistant Prostate Cancer
4
Metastatic Castration-resistant Prostate Cancer
4
Prostatic Diseases
3
Neoplasms
3
Breast Neoplasms
3
Urogenital Neoplasms
2
Triple Negative Breast Neoplasms
2
Salivary Gland Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Hormone-sensitive Prostate Cancer
2
Male Urogenital Diseases
2
Genital Diseases, Male
2
Bulbo-Spinal Atrophy, X-Linked
2
Biochemically Recurrent Prostate Cancer
2
Adenocarcinoma
2
Urogenital Diseases
1
Thrombocytosis
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Non-Metastatic
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Non-metastatic Prostate Cancer
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostate Cancer Non-Metastatic
×
darolutamide
×
Clear all
NCT02200614
2022-06-28
ARAMIS
Bayer
Phase 3
Completed
1,509 enrolled
13 charts
1 FDA